Sofinnova's Window on Early-Stage Technology in Europe
This article was originally published in Start Up
In Europe, one of the historical obstacles to company creation has been a lack of venture capital funding. Not any longer. Abingworth's life-science-focused fund, Abingworth Bioventures IV, raised $350 million; Schroder Ventures Life Sciences' fund International Life Sciences III was $402 million; and the latest life sciences fund of Techno Venture Management was $450 million. These funds now rival their counterparts on the East Coast or the Bay area of the US. Now, the Paris-based venture capital firm Sofinnova Partners has closed its fifth fund, at €385 million ($516 million). Sofinnova Capital V is perhaps the largest European fund dedicated to early-stage investing in life sciences and IT, with a focus on European companies.
You may also be interested in...
Big Pharma spin-outs may on average have raised 50% more private money than non-spin-outs over the last five years, but it's not yet clear whether they always deliver better returns on investment. Still, spin-outs remain an investor favorite, and in Europe are becoming the mainstay of a sustainable biopharma industry.
Europe's financing environment makes it difficult to build big biotech from scratch. But sustainable biopharma firms are nevertheless emerging--mostly through the transformation of existing pharma assets.
Because of a conservative clinical culture and a skittish venture community, medical-device company creation has lagged in Europe. The reasons for the lack of device company creation are several: a physician community that is not only not entrepreneurial, but often averse to capitalizing on commercial opportunities; a venture capital community unfamiliar with devices; and a lack of